Effect of pretreatment with omega-3 polyunsaturated fatty acids (PUFAs) on hematological parameters and platelets aggregation in patients during elective coronary artery bypass grafting;Efekat omega-3 polinezasicenih masnih kiselina na hematološke parametre i agregaciju trombocita kod elektivne revaskularizacije srca

Vojnosanitetski Pregled

Volumn 70, Issue 4, 2013, Pages 396-402

  Veljović, Milić ^a,b   Mihajlović, Ivana ^c   Subota, Vesna ^a   Antunović, Mirjana ^a,b   Jevdjić, Jasna ^d   Udovicić, Ivo ^a   Popadić, Ana ^a   Vulović, Tatjana ^d  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b Serbia   (Serbia)

^c Medicines and Medical Devices Agency of Serbia   (Serbia)

^d Clinical Center 'Kragujevac'   (Serbia)

Author keywords

Coronary artery bypass; Fatty acids; Hematologic tests; Hemorrhage; Omega 3; Platelet agregation

Indexed keywords

ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; HEMOGLOBIN; OMEGAVE; OMEGAVEN; PLACEBO; THROMBIN RECEPTOR ACTIVATING PEPTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; ELECTIVE SURGERY; EXTRACORPOREAL CIRCULATION; FEMALE; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PREOPERATIVE TREATMENT; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; THROMBOCYTE AGGREGATION;

AGED; BLOOD LOSS, SURGICAL; CORONARY ARTERY BYPASS; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PREOPERATIVE CARE;

EID: 84875786374     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP1304396V     Document Type: Article

References (45)

1. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453-1462.
2. Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114(8): 774-782.
3. Christensen MC, Krapf S, Kempel A, von Heymann C. Costs of excessive postoperative hemorrhage in cardiac surgery. J Thorac Cardiovasc Surg 2009; 138(3): 687-693.
4. Moulton MJ, Creswell LL, Mackey ME, Cox JL, Rosenbloom M. Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111(5): 1037-1046.
5. Park Y, Harris W. EPA, but not DHA, decreases mean platelet volume in normal subjects. Lipids 2002; 37(10): 941-946.
6. Hendra T, Betteridge DJ. Platelet function, platelet prostanoids and vascular prostacyclin in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids 1989; 35(3): 197-212.
7. Raheja BS. Role of nutrition in the pathogenesis of NIDDM. J Assoc Physicians India 1993; (Suppl 1): 18-24.
8. Mozaffarian D, Marchioli R, Gardner T, Ferazzeti P, O'Gara P, Latini R, et al. The w-3 fatty acids for prevention of postoperative atrial fibrillation (OPERA) trial-rationale and design. Am Heart J 2011; 162(3): 56-63.e3.
9. Wang C, Chung M, Lichtenstein A, Balk E, Kupelnick B, DeVine D, et al. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess (Summ) 2004; (94): 1-8.
10. Balk E, Chung M, Lichtenstein A, Chew P, Jupelnick B, Lawrence A, et al. Effects of omega-3 fatty acids on cardiovascular risk factors and intermediate markers of cardiovascular disease. Evid Rep Technol Assess (Summ) 2004; (93): 1-6.
11. Reis GJ, Boucher TM, Sipperly ME, Silverman DI, McCabe CH, Baim DS, et al. Randomised trial of fish oil for prevention of restenosis after coronary angioplasty. Lancet 1989; 2(8656):177-181.
12. Veljovic M, Popadic A, Vukic Z, Ilic R, Trifunovi Z, Mandaric V, et al. Myocardial protection during elective coronary artery bypasses grafting by pretreatment of omega-3 polyunsaturated fatty acids. Vojnosanit Pregl 2013; (In Press).
13. Mozaffarian D, Wu JH. Omega-3 fatty ccids and cardiovascular disease; Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol, 2011; 58(20): 2047-2067.
14. Toth O, Calais A, Penz S, Losonczy H, Siess W. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006; 96(6): 781-788.
15. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M. Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 1996; 77(1): 31-36.
16. DeCaterina R, Giannessi D, Mazzone A, Bernini W, Lazzerini G, Maffei S, et al. Vascular prostacyclin is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery. Circulation 1990; 82(2): 428-438.
17. Mariscalco G, Braga SS, Banach M, Borsani P, Bruno VD, Napoleone M, et al. Preoperative n-3 polyunsatured fatty accids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology 2010; 61(7): 643-650.
18. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, Shearman CP, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 2003; 361(9356): 477-485.
19. Rapp JH, Connor WE, Lin DS, Porter JM. Dietary eicosapentae-noic acid and docosahexaenoic acid from fish oil: their incorporation into advanced human atherosclerotic plaques. Arte-rioscler Thromb 1991; 11(4): 903-911.
20. Johansen O, Brekke M, Seljeflot I, Abdelnoor M, Arnesen H N-3 fatty acids do not prevent restenosis after coronary angioplasty: results from the CART study. Coronary Angioplasty Restenosis Trial. J Am Coll Cardiol 1999; 33(6): 1619-1626.
21. Maresta A, Balduccelli M, Varani E, Marzilli M, Galli C, Heiman F, et al. Prevention of postcoronary angioplasty restenosis by omega-3 fatty acids: main results of the Esapent for Prevention of Restenosis ITalian Study (ESPRIT). Am Heart J 2002; 143(6): E5.
22. Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol 2010; 55(16): 1671-1678.
23. Bays HE. Safety considerations with omega-3 fatty acid therapy. Am J Cardiol 2007; 99(6A): 35C-43C.
24. Muriithi EW, Belcher PR, Rao JN, Chaudhry MA, Nicol D, Wheat-ley DJ. The effects of heparin and extracorporeal circulation on platelet counts and platelet microaggregation during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2000; 120(3): 538-543.
25. Makar M, Taylor J, Zhao M, Farrohi A, Trimming M, Dattellis N. Perioperative coagulopathy, bleeding, and hemostasis during cardiac surgery. A comprehensive review. ICU Director 2010; 1(1): 17-27.
26. Dacey LJ, Munoz JJ, Baribeau YR, Johnson ER, Lahey SJ, Leavitt BJ, et al. Reexploration for hemorrhage following coronary artery bypass grafting: Incidence and risk factors. Northern New England Cardiovascular Disease Study Group. Arch Surg 1998; 133(4): 442-447.
27. Frumento RJ, OMalley CM, Bennett-Guerrero E. Stroke after cardiac surgery: A retrospective analysis of the effect of aprotinin dosing regimens. Ann Thorac Surg 2003; 75(2): 479-483; discussion 483-84.
28. Basran S, Frumento RJ, Cohen A, Lee S, Du Y, Nishanian E, et al. The association between duration of storage of transfused red blood cells and morbidity and mortality after reoperative cardiac surgery. Anesth Analg 2006; 103(1): 15-20.
29. Spiess BD, Royston D, Levy JH, Fitch J, Dietrich W, Body S, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion 2004; 44(8):1143-1148.
30. Seyfert UT, Haubelt H, Vogt A, Hellstern P. Variables influencing Multiplate(TM) whole blood impedance platelet aggregometry and turbidimetric platelet aggregation in healthy individuals. Platelets 2007; 18(3): 199-206.
31. Rahe-Meyer N, Winterhalter M, Boden A, Froemke C, Pipenbrock S, Calatzis A, et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009; 53(2): 168-175.
32. von Pape KW, Dzijan-Horn M, Bohner J, Spannagl M, Weisser H, Calatzis A. Control of aspirin effect in chronic cardiovascular patients using two whole blood platelet function assays. PFA-100 and Multiplate. Hamostaseologie 2007; 27(30): 155-160, quiz 161-2. (German)
33. Sibbing D, von Beckerath O, Schomig A, Kastrati A, von Beckerath N. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis 2007; 18(4): 335-339.
34. Paniccia R, Antonucci E, Maggini N, Romano E, Gori AG, Marcucci R, et al. Assessment of Platelet Function on Whole Blood by Multiple Electrode Aggregometry in High-Risk Patients With Coronary Artery Disease Receiving Antiplatelet Therapy. Am J Clin Pathol 2009; 131(6): 834-842.
35. Mengistu AM, Wolf MW, Boldt J, Rohm KD, Lang J, Piper SN. Evaluation of a new platelet function analyzer in cardiac surgery: a comparison of modified thromboelastography and whole-blood aggregometry. J Cardiothorac Vasc Anesth 2008; 22(1): 40-46.
36. Görlinger K, Jambor C, Hanke AA, Dirkmann D, Adamzik M, Hartmann M, et al. Perioperative coagulation management and control of platelet transfusion by point-of-care platelet function analysis. Transfus Med Hemother 2007; 34(6): 396-411.
37. Steinlechner B, Dworschak M, Birkenberg B, Duris M, Zeidler P, Fischer H, et al. Platelet dysfunction in outpatients with left ventricular assist devices. Ann Thorac Surg 2009; 87(1): 131-137.
38. Rahe-Meyer N, Winterhalter M, Hartmann J, Pattison A, Hecker H, Calais A, et al. An evaluation of cyclooxygenase-1 inhibition before coronary artery surgery: aggregometry versus patient self-reporting. Anesth Analg 2008; 107(6): 1791-1797.
39. Rahe-Meyer N, Winterhalter M, Boden A, Froemke C, Pipenbrock S, Calais A, et al. Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry. Acta Anaesthesiol Scand 2009; 53(2): 168-175.
40. von Schacky C, Weber PC. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexae-noic acids in humans. J Clin Invest 1985; 76(6): 2446-2450.
41. Thorngren M, Gustafson A. Effects of 11-week increases in dietary eicosapentaenoic acid on bleeding time, lipids, and platelet aggregation. Lancet 1981; 2(8257): 1190-1193.
42. Kwon JS, Snook JT, Wardlaw GM, Wardlaw GM, Hwang DH. Effects of diets high in saturated fatty acids, canola oil, or saf-flower oil on platelet function, thromboxane B2 formation, and fatty acid composition of platelet phospholipids. Am J Clin Nutr 1991; 54(2): 351-358.
43. Freese R, Mutanen M, Valsta LM, Salminen I. Comparison of the effects of two diets rich in monounsaturated fatty acids differing in their linoleic/alpha-linolenic acid ratio on platelet aggregation. Thromb Haemost 1994; 71(1): 73-77.
44. Cairns JA, Gill J, Morton B, Roberts R, Gent M, Hirsh J, et al. Fish oils and lowmolecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary an-gibplasty. The EMPAR Study. Circulation 1996; 94(7): 1553-1560.
45. Serebruany VL. Aggressive antiplatelet strategies: time to reconsider? Eur Heart J 2007; 28(18): 2183-2184.